Hayley C Whitaker
Uro-Oncology Research Group, UK Cambridge Research Institute, United Kingdom
Dr. Hayley C Whitaker was research Associate in UK Cambridge Research Institute Ribson Way.
Androgens and the AR are essential for prostate cancer growth and development and if we can bypass this pathway we may be able to target cancer. Following treatment with antiandrogens prostate cancer becomes hormone resistant and we do not understand how this transition occurs. The current test for prostate cancer is the PSA test but this frequently gives false positives and negatives so we are looking for a new biomarker for either the development of prostate cancer or its progression to the hormone resistant form.